Annual CFO
-$140.88 M
+$889.00 K+0.63%
31 December 2023
Summary:
Adaptimmune Therapeutics annual cash flow from operations is currently -$140.88 million, with the most recent change of +$889.00 thousand (+0.63%) on 31 December 2023. During the last 3 years, it has fallen by -$87.29 million (-162.88%). ADAP annual CFO is now -482.46% below its all-time high of $36.84 million, reached on 30 June 2014.ADAP Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$54.45 M
-$101.85 M-214.88%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly cash flow from operations is currently -$54.45 million, with the most recent change of -$101.85 million (-214.88%) on 30 September 2024. Over the past year, it has dropped by -$9.29 million (-20.58%). ADAP quarterly CFO is now -140.66% below its all-time high of $133.93 million, reached on 31 December 2021.ADAP Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$53.68 M
-$9.29 M-20.93%
30 September 2024
Summary:
Adaptimmune Therapeutics TTM cash flow from operations is currently -$53.68 million, with the most recent change of -$9.29 million (-20.93%) on 30 September 2024. Over the past year, it has increased by +$70.48 million (+56.77%). ADAP TTM CFO is now -600.31% below its all-time high of $10.73 million, reached on 31 December 2021.ADAP TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +0.6% | -20.6% | +56.8% |
| 3 y3 years | -162.9% | -20.5% | +64.8% |
| 5 y5 years | -35.0% | -83.9% | +59.2% |
ADAP Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1413.1% | +0.6% | -140.7% | at low | -600.3% | +64.8% |
| 5 y | 5 years | -1413.1% | +0.6% | -140.7% | at low | -600.3% | +64.8% |
| alltime | all time | -482.5% | +0.6% | -140.7% | at low | -600.3% | +64.8% |
Adaptimmune Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$54.45 M(-214.9%) | -$53.68 M(+20.9%) |
| June 2024 | - | $47.40 M(-248.4%) | -$44.39 M(-67.3%) |
| Mar 2024 | - | -$31.95 M(+117.7%) | -$135.55 M(-3.8%) |
| Dec 2023 | -$140.88 M(-0.6%) | -$14.68 M(-67.5%) | -$140.88 M(+13.5%) |
| Sept 2023 | - | -$45.16 M(+3.2%) | -$124.16 M(-2.4%) |
| June 2023 | - | -$43.76 M(+17.4%) | -$127.16 M(+2.0%) |
| Mar 2023 | - | -$37.28 M(-1925.8%) | -$124.65 M(-12.1%) |
| Dec 2022 | -$141.77 M(-1421.4%) | $2.04 M(-104.2%) | -$141.77 M(+1334.5%) |
| Sept 2022 | - | -$48.16 M(+16.7%) | -$9.88 M(+42.7%) |
| June 2022 | - | -$41.25 M(-24.2%) | -$6.92 M(-341.4%) |
| Mar 2022 | - | -$54.40 M(-140.6%) | $2.87 M(-73.3%) |
| Dec 2021 | $10.73 M(-120.0%) | $133.93 M(-396.3%) | $10.73 M(-107.0%) |
| Sept 2021 | - | -$45.20 M(+43.7%) | -$152.41 M(+23.4%) |
| June 2021 | - | -$31.46 M(-32.4%) | -$123.53 M(+5.6%) |
| Mar 2021 | - | -$46.54 M(+59.3%) | -$116.99 M(+118.3%) |
| Dec 2020 | -$53.59 M(-52.4%) | -$29.22 M(+79.1%) | -$53.59 M(+45.2%) |
| Sept 2020 | - | -$16.32 M(-34.5%) | -$36.90 M(-26.5%) |
| June 2020 | - | -$24.91 M(-247.8%) | -$50.19 M(-15.6%) |
| Mar 2020 | - | $16.86 M(-234.6%) | -$59.45 M(-47.2%) |
| Dec 2019 | -$112.51 M | -$12.53 M(-57.7%) | -$112.51 M(-14.5%) |
| Sept 2019 | - | -$29.61 M(-13.3%) | -$131.66 M(+42.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | -$34.17 M(-5.6%) | -$92.12 M(-1.3%) |
| Mar 2019 | - | -$36.20 M(+14.3%) | -$93.31 M(-10.6%) |
| Dec 2018 | -$104.39 M(+92.2%) | -$31.68 M(-418.8%) | -$104.39 M(+11.0%) |
| Sept 2018 | - | $9.94 M(-128.1%) | -$94.06 M(+3.9%) |
| June 2018 | - | -$35.36 M(-25.2%) | -$90.51 M(+23.7%) |
| Mar 2018 | - | -$47.28 M(+121.4%) | -$73.16 M(+34.7%) |
| Dec 2017 | -$54.31 M(+12.8%) | -$21.36 M(-258.3%) | -$54.31 M(+77.6%) |
| Sept 2017 | - | $13.49 M(-174.9%) | -$30.59 M(-48.5%) |
| June 2017 | - | -$18.01 M(-36.7%) | -$59.44 M(+2.6%) |
| Mar 2017 | - | -$28.44 M(-1300.0%) | -$57.93 M(+20.3%) |
| Dec 2016 | -$48.17 M(+166.7%) | $2.37 M(-115.4%) | -$48.17 M(-4.7%) |
| Sept 2016 | - | -$15.37 M(-6.8%) | -$50.54 M(+42.6%) |
| June 2016 | - | -$16.49 M(-11.7%) | -$35.44 M(+87.1%) |
| Mar 2016 | - | -$18.68 M(+6903.7%) | -$18.95 M(+717.4%) |
| Dec 2015 | -$18.06 M(-39.1%) | - | - |
| Sept 2015 | - | -$266.70 K(-87.0%) | -$2.32 M(-84.7%) |
| June 2015 | -$29.67 M(-180.5%) | - | - |
| Dec 2014 | - | -$2.05 M(-84.3%) | -$15.15 M(+15.7%) |
| Sept 2014 | - | -$13.10 M | -$13.10 M |
| June 2014 | $36.84 M(-574.4%) | - | - |
| June 2013 | -$7.77 M | - | - |
FAQ
- What is Adaptimmune Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual CFO year-on-year change?
- What is Adaptimmune Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly CFO year-on-year change?
- What is Adaptimmune Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics TTM CFO year-on-year change?
What is Adaptimmune Therapeutics annual cash flow from operations?
The current annual CFO of ADAP is -$140.88 M
What is the all time high annual CFO for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual cash flow from operations is $36.84 M
What is Adaptimmune Therapeutics annual CFO year-on-year change?
Over the past year, ADAP annual cash flow from operations has changed by +$889.00 K (+0.63%)
What is Adaptimmune Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ADAP is -$54.45 M
What is the all time high quarterly CFO for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly cash flow from operations is $133.93 M
What is Adaptimmune Therapeutics quarterly CFO year-on-year change?
Over the past year, ADAP quarterly cash flow from operations has changed by -$9.29 M (-20.58%)
What is Adaptimmune Therapeutics TTM cash flow from operations?
The current TTM CFO of ADAP is -$53.68 M
What is the all time high TTM CFO for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high TTM cash flow from operations is $10.73 M
What is Adaptimmune Therapeutics TTM CFO year-on-year change?
Over the past year, ADAP TTM cash flow from operations has changed by +$70.48 M (+56.77%)